{
    "title": "FDA approves Blueprint's stomach cancer therapy priced at $32,000 per month",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-7870621/U-S-FDA-approves-Blueprints-therapy-rare-type-stomach-cancer.html",
    "date": "2020-01-09",
    "keywords": [
        "cancer",
        "mutation",
        "blueprint",
        "therapy",
        "treatment",
        "company",
        "chander",
        "saumya",
        "joseph",
        "drug",
        "stomach",
        "intestine",
        "gist",
        "ayvakit",
        "price",
        "surgery",
        "haviland",
        "jan",
        "food",
        "administration",
        "form",
        "agency",
        "thursday",
        "decision",
        "subset",
        "tumor",
        "specialty",
        "pharmacy",
        "network",
        "week",
        "acquisition",
        "cost",
        "supply",
        "regardless",
        "dosage",
        "list",
        "outofpocket",
        "duration",
        "healthcare",
        "type",
        "softtissue",
        "sarcoma",
        "risk",
        "year",
        "pdgfra",
        "exon",
        "median",
        "impact",
        "progression",
        "time",
        "officer",
        "kate",
        "phone",
        "interview",
        "offtarget",
        "novartis",
        "improvement",
        "milestone",
        "indication",
        "cowen",
        "analyst",
        "marc",
        "frahm",
        "fda",
        "approval",
        "care",
        "population",
        "sibi",
        "bengaluru",
        "editing",
        "aditya",
        "soni"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}